Novel hemocyanin protein adjuvant for animal vaccine market.

Mikota Ltd与加的夫大学和皇家兽医学院(伦敦大学)合作，正在评估一种新的蛋白质佐剂作为疫苗交付平台，主要针对伴侣和牲畜市场。该项目建立在Mikota早期的血蓝蛋白工作的基础上，以创造新的结构来解决研究表明，伴侣动物和牲畜可能是潜在的无症状新冠肺炎携带者。该项目的输出将证明Mikota的生物蓝蛋白构建物在小鼠模型中作为疫苗佐剂的有效性。这项工作将在未来的动物试验中得到扩展，有望为未来在人类新冠肺炎疫苗或其他冠状病毒疫苗中的潜在使用提供证据。

Mikota Ltd in collaboration with Cardiff University and Royal Veterinary College (University of London) are evaluating a new protein adjuvant as a vaccine delivery platform, primarily aimed at the companion and livestock market.This project is building on Mikota's earlier hemocyanin work in creating novel constructs to address research demonstrating that companion animals and livestock may be potential asymptomatic COVID-19 carriers.The outputs from this project will demonstrate the efficacy of Mikota's BioCyanin constructs as a vaccine adjuvant in a mouse model. This work will be expanded in future animal trials which are expected to lead to evidence for potential future use in human COVID-19 vaccines, or other coronavirus vaccines.